News ImmuneRegen NewsJuly 12, 2007 7:00 AM ET ImmuneRegen BioSciences Announces Development Partnership With Uluru Inc.SCOTTSDALE, Ariz., July 12 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), announced its first co-development partnership in the company's history. ImmuneRegen has signed a strategic partnership with Uluru Inc. (OTC Bulletin Board: ULUR) to co-develop the combination of Uluru's hydrogel nanoparticle biomaterial and ImmuneRegen's Homspera(TM) into a potential wound healing treatment. According to the development agreement, ImmuneRegen and Uluru will establish a Joint Steering Committee to oversee the development project. The partnership will include an undetermined number of in vitro and in vivo studies on the potential wound healing effects of Homspera, to be underwritten by Uluru. ImmuneRegen and Uluru will consider entering into a license agreement to take any developed wound healing product to market. "We are proud to have entered into our first co-development partnership and look forward to a prosperous relationship with such a high quality company as Uluru," says ImmuneRegen CEO, Michael K. Wilhelm. "We are hopeful that this project will result in an ImmuneRegen-Uluru product that could deliver significant benefits to the user and to the medical community." Previous tests in small animals as well as supportive data from third- parties have revealed evidence leading management to believe that the use of Homspera could be effective in accelerating the wound healing process. Homspera has also shown efficacy in small animals at protecting against lethal radiation and microbiological attack (specifically influenza and anthrax spores), and has shown indications of being protective against specific inhaled noxious chemicals. About Uluru, Inc. Uluru, Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology. For further information about ULURU Inc., please visit http://www.uluruinc.com. About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|